Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging

• Biophytis SA (NASDAQ: BPTS) has announced top-line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in sarcopenia patients.

• Sarcopenia is a condition characterized by loss of skeletal muscle mass and function.

• The trial tested two doses of Sarconeos (BIO101), 175 mg bid and 350 mg bid, compared to placebo on gait speed measured by the 400-Meter Walk Test (400 MWT), the primary endpoint of the study.

• The highest dose of 350 mg bid showed a clinically meaningful improvement compared to placebo in gait speed after six months of treatment, of 0.09 m/s in the Full Analysis Dataset (FAS) population and 0.10 m/s Per-Protocol (PP) population.

• The 350 mg bid was associated with a reduction in mobility disability and mortality in the elderly.

• The 175 mg bid did not show a clinically meaningful difference compared to placebo in gait in both the population groups.

• No treatment effect was detected on the handgrip strength test and the PF10 sub-score of the SF-36 PRO on mobility disability, key secondary endpoints of the study.

• Sarconeos showed a favorable safety profile after up to 9 months of dosing, with no significant difference between treatments arms and placebo for Adverse Events, Serious Adverse Events, safety laboratory parameters, and vital signs.

• Adverse Events (AEs) percentages - were 36%, 37%, and 27% of the AEs for the placebo, 175 mg bid, 350 mg bid treatments, respectively.

• Serious AEs percentages - were 45%, 42% and 12% for placebo, 175 mg bid, 350 mg bid respectively.

• None of the Serious AEs were related to the treatment.

• Price Action: BPTS shares traded higher by 28% at $10.99 in premarket trading on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis

• Oncology-Focused Biotech Immuneering Jumps To Wall Street With 2M IPO

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.